Keros Therapeutics Is Maintained at Buy by Truist Securities

Dow JonesDec 23 20:51 · Ratings

Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $43

Futu NewsDec 23 20:33 · Ratings

Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating

MT NewswiresDec 23 19:52 · Ratings

Analyst's Buy Rating on Keros Therapeutics Driven by Strategic Partnerships and Market Potential

TipRanksDec 23 19:45 · Ratings

Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $63

Futu NewsDec 16 21:31 · Ratings

Oppenheimer Maintains Outperform on Keros Therapeutics, Lowers Price Target to $63

BenzingaDec 16 21:02 · Ratings